Replimune Stock Surges 131% Following FDA Acceptance of Resubmitted RP1 Application for Advanced Melanoma
核心洞察
Replimune's shares have surged 131.1% over three months following FDA acceptance of the resubmitted biologics license application for RP1 in combination with Bristol Myers' Opdivo for advanced melanoma (搜索) treatment.
The FDA has set a target action date of April 10, 2026, for the RP1/Opdivo combination, which previously received Breakthrough Therapy designation for patients who had received prior anti-PD1 (搜索) therapy.
Recent IGNYTE phase II study data showed the RP1/Opdivo combination achieved a 44% objective response rate with 11.9 months median duration of response in acral melanoma (搜索) patients.
Replimune Group (搜索)'s shares have experienced a remarkable 131.1% surge over the past three months, driven by positive regulatory developments surrounding the company's lead oncolytic immunotherapy candidate RP1. The biotech company's stock momentum reflects renewed investor confidence following the FDA's acceptance of a resubmitted biologics license application for RP1 in combination with Bristol Myers Squibb (搜索)'s Opdivo (nivolumab) for treating advanced melanoma (搜索).
FDA Accepts Resubmitted Application After Initial Setback
In October, the FDA accepted Replimune's resubmitted BLA for the RP1/Opdivo combination, setting a target action date of April 10, 2026. This acceptance came after the company addressed concerns raised in a complete response letter issued in July 2025, where the FDA cited issues regarding data heterogeneity in the IGNYTE study population and questioned whether the study constituted an adequate and well-controlled clinical investigation.
The FDA had stated that the IGNYTE study was not considered capable of providing substantial evidence of effectiveness and required clarification on certain aspects of the confirmatory trial's study design, including the contribution of individual components. Notably, the agency raised no safety concerns in its initial rejection.
Following extensive engagement with the FDA, including meetings to address the rejected application, the regulatory body confirmed that the resubmission adequately addresses the concerns outlined in the prior complete response letter.
Clinical Data Demonstrates Promising Efficacy
The RP1/Opdivo combination has shown encouraging clinical results across multiple melanoma subtypes. In October, Replimune reported positive data from an IGNYTE phase II study presented at the ESMO Congress, highlighting promising outcomes specifically in acral melanoma (搜索). In this patient cohort, the RP1/Opdivo combination achieved an objective response rate of 44% with a median duration of response of 11.9 months.
The FDA had previously granted Breakthrough Therapy designation to RP1 in combination with Opdivo for treating adult patients with advanced melanoma (搜索) who had previously received an anti-PD1 (搜索)-containing regimen. The combination was accepted for review under the FDA's Priority Review pathway in January 2025.
Replimune is continuing a larger phase III study evaluating the RP1/Opdivo combination versus physician's choice of treatment in melanoma patients who progressed on anti-PD1 (搜索) and anti-CTLA-4 (搜索) therapies. The company has also shared encouraging data demonstrating the safety and efficacy of the combination for treating patients with non-melanoma skin cancers (搜索).
Expanding Pipeline and Market Interest
Beyond the lead melanoma indication, RP1 is being evaluated as a monotherapy in solid organ transplant recipients with skin cancers. Replimune's pipeline includes a second oncolytic immunotherapy candidate, RP2, currently being evaluated in mid-stage to large-stage studies for metastatic uveal melanoma (搜索) and hepatocellular carcinoma (搜索) treatment.
The regulatory progress has attracted significant institutional attention. Recent filings show substantial increases in holdings by major investment firms, with Balyasny Asset Management (搜索) expanding its position by 507.4%, acquiring over 2.6 million shares. Erste Asset Management (搜索) reported an increase exceeding 13,000% during the last reporting period.
Options Activity Signals Growing Investor Confidence
Trading activity on January 6 revealed a significant shift in market positioning, with investors purchasing 12,092 call contracts, representing a 142% increase over the daily average volume of approximately 5,002 contracts. This aggressive accumulation of calls indicates pronounced bullish sentiment among options traders.
The underlying equity showed a positive response, with shares recently trading at $8.45 after a previous close of $8.29. Despite this uptick, the stock remains down approximately 19.6% year-to-date, underperforming the broader biotechnology sector's 20.2% growth.
Financial Position and Upcoming Catalysts
Replimune maintains a strong financial position with a confirmed cash position of $323.6 million, projected to fund operations through the end of 2026. The company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14 at 1:30 PM Pacific Time, where management is expected to provide updates on its clinical pipeline and strategy for its RPx platform.
Analyst consensus currently rates the stock a "Moderate Buy" with an average price target of $11.00. The confluence of heavy call volume and institutional buying suggests that market participants view the clinical risks ahead of the April 2026 PDUFA date as partially mitigated, positioning Replimune for a potentially pivotal period in its development trajectory.